Palbociclib 125mg trials for Breast cancer

All Palbociclib 125mg trials · All Breast cancer trials

Phase breakdown

Recruiting trials studying Palbociclib 125mg for Breast cancer

• A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
  NCT07002177 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Combined Immunotherapies in Metastatic ER+ Breast Cancer
  NCT04563507 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: Female · 3 locations
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
  NCT06307249 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 73 locations

Common questions

How many trials study Palbociclib 125mg for Breast cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.